ENTX Entera Bio

Entera Bio to Present at the H.C. Wainwright 6th Annual Israel Conference

Entera Bio to Present at the H.C. Wainwright 6th Annual Israel Conference

BOSTON and JERUSALEM, Nov. 02, 2020 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of orally delivered large molecule therapeutics, announced that members of its management team will host a virtual presentation at the H.C. Wainwright Annual Israel Conference on Thursday, November 12, 2020 at 8:00 a.m. ET.

To access a live webcast of the fireside chat on the “Investor Relations” page of Entera’s website, please click . A replay of the webcast will be archived on Entera’s website for approximately 45 days following the presentation.

About Entera Bio

Entera is a leader in the development of orally delivered macromolecule therapeutics for use in areas with significant unmet medical need where adoption of injectable therapies is limited due to cost, convenience and compliance challenges for patients. The Company’s proprietary, oral drug delivery technology is designed to address the technical challenges of poor absorption, high variability, and the inability to deliver large molecules to the targeted location in the body through the use of a synthetic absorption enhancer to facilitate the absorption of large molecules, and protease inhibitors to prevent enzymatic degradation and support delivery to targeted tissues. The Company’s most advanced product candidates, EB613 for the treatment of osteoporosis and EB612 for the treatment of hypoparathyroidism are in Phase 2 clinical development. Entera also licenses its technology to biopharmaceutical companies for use with their proprietary compounds and, to date, has established a collaboration with Amgen Inc. For more information on Entera Bio, visit .

Contact:

Jonathan Lieber, CFO
Tel:  79
EN
02/11/2020

Underlying

ENTXEntera Bio

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Entera Bio

 PRESS RELEASE
Free
ENTX ENTERA BIO

Entera Bio Reports Positive PK Data for First-in-Class Oral GLP-2 Tabl...

Entera Bio Reports Positive PK Data for First-in-Class Oral GLP-2 Tablet Treatment for Patients with Short Bowel Syndrome at the 2025 ESPEN Congress Preclinical Data for OPK-8801003 Demonstrate Substantially Longer Biological Half-Life with Peak Plasma Levels Comparable to Gattex®, the Only Approved GLP-2 Therapy Oral GLP-2 Tablet Could Transform Treatment Paradigm for 30,000 Short Bowel Syndrome (SBS) Patients Currently Dependent on Daily Injections of the Peptide JERUSALEM, Sept. 15, 2025 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of oral peptides...

September 15, 2025 1 EN
 PRESS RELEASE
Free
ENTX ENTERA BIO

Entera Bio Presents Positive Effects of EB613 on Both Trabecular and C...

Entera Bio Presents Positive Effects of EB613 on Both Trabecular and Cortical Bone in Postmenopausal Women with Osteoporosis at ASBMR 2025 EB613 Demonstrates Significant Effects on Both Trabecular and Cortical Bone Compartments After Just 6 Months of Treatment in Phase 2 Study; Cortical Improvements Comparable to Injectable Teriparatide and Abaloparatide Company Plans to Initiate Global Registrational Phase 3 Study Following July 2025 FDA Concurrence Entera also Presented Promising Pharmacokinetic Data for Next-Gen EB613 Single Tablet Candidate as Potential Future Franchise Extension JE...

September 8, 2025 1 EN
 PRESS RELEASE
Free
ENTX ENTERA BIO

Entera Bio to Unveil Clinical and Non-Clinical Data Across 3 Oral Pept...

Entera Bio to Unveil Clinical and Non-Clinical Data Across 3 Oral Peptide Programs at Upcoming September Conferences Osteoporosis Program: Phase 2 analysis exploring the dual actions of oral PTH(1-34) tablet treatment, EB613 on trabecular and cortical bone, and Next-Gen EB613 PK/PD data slated for oral and poster presentations at ASBMRShort Bowel Syndome and Rare GI Disorders: PK/PD of oral GLP-2 tablet candidate poster presentation at ESPENCorporate Overview at H.C. Wainwright Investor Conference JERUSALEM, Aug. 28, 2025 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), a leader in th...

August 28, 2025 1 EN
 PRESS RELEASE
Free
ENTX ENTERA BIO

Entera Bio Announces Second Quarter 2025 Financial Results and Busines...

Entera Bio Announces Second Quarter 2025 Financial Results and Business Updates FDA provides pivotal agreement on EB613 Phase 3 design, confirming Bone Mineral Density (BMD) as primary endpoint and clearing streamlined pathway for first oral anabolic osteoporosis treatmentSignificant regulatory and pipeline advancements achieved including FDA waiver of additional safety studies and next-gen EB613 expected to enter Phase 1 in November 2025Strong momentum across OPKO collaboration with obesity program showing promising preclinical data; and EB612 oral PTH directed hypoparathyroidism program c...

August 8, 2025 1 EN
 PRESS RELEASE
Free
ENTX ENTERA BIO

Entera Bio Receives FDA Agreement on BMD as Primary Endpoint for EB613...

Entera Bio Receives FDA Agreement on BMD as Primary Endpoint for EB613 Registrational, Phase 3 Study in Post-Menopausal Women with Osteoporosis JERUSALEM, July 28, 2025 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of oral peptides and protein replacement therapies, announced today that in a written response to a Type A meeting request, the U.S. Food and Drug Administration (FDA) agreed with the Company’s proposal that the NDA marketing application filing for EB613 would be supported by a single multinational, randomized, double-blind, placebo-controlled,...

July 28, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch